How a health system is financed has a big impact on how people access health services, how much they pay for their care, which services are provided, and how well they are provided. Through our state-of-the-art research and economic analyses, training, and technical assistance, we help ministries of health and finance, donor agencies, universities and other organizations think through their health sector financing needs, where their spending will have the greatest impact, and how to raise the needed resources.
By fostering access to economic and health information tools, we advance the use of evidence to help ensure local health systems, policies, and interventions are appropriately financed to achieve large and lasting health gains.
As countries take the lead in financing their health systems, donors will have new roles and responsibilities to respond to emerging global health challenges. In this era of changing health aid, we work with donors and development agencies to generate evidence on emerging health investment priorities, convene experts to create new financing and economic paradigms, and provide technical assistance to implement these new models.
Consortium to Assess Prevention Economics
The Consortium to Assess Prevention Economics, a multi-million dollar cooperative agreement, aims to improve policy-relevant economic modeling of disease prevention in five areas: HIV, hepatitis, sexually transmitted infections (STI), tuberculosis(TB), and school health.
Global Health Economics Consortium
The Global Health Economics Consortium brings together UCSF health economists and colleagues at UC Berkeley and Stanford to support the capacity of national and local jurisdictions to design and deliver efficient, high-quality preventive and treatment health services.
Health Financing for Malaria
The Malaria Elimination Initiative generates new evidence on economics and financing by: researching the costs and benefits of elimination, developing national and regional investment cases for elimination, monitoring financing flows to eliminating countries, analyzing the impact of policy and financing decisions on eliminating countries, researching the cost-effectiveness of malaria elimination interventions, and assessing and recommending possible programmatic cost-efficiencies.
The Lancet Commission on Investing in Health
The Commission is an independent group of 25 leading economists and global health experts from around the world. Their report, Global Health 2035, puts forward an ambitious health policy agenda to achieve dramatic improvements in global health by 2035. The Commission Secretariat at GHS advances these analyses to help inform policy decisions.
2016 World Innovation Summit for Health
The World Innovation Summit for Health (WISH) Forum on the Economic Benefits of Investing in Health synthesizes the best evidence on the economic value of health investments and draws out practical and policy implications for national governments and donor agencies.
Working Group on International Collective Action in Global Health
This initiative, for which GHS is a core research partner, focused on identifying and assessing priorities for future donor financing in global health.
Investing in Health: The Economic Case
The Inclusive Cost of Pandemic Influenza Risk
- Naomi Beyeler, MPH, MCP
- Neelam Feachem, MS
- Sara Fewer. MPP, MPH
- Eric Goosby, MD
- Dean Jamison, PhD
- James G. Kahn, MD, MPH
- Amy Lockwood, MBA
- Rima Shretta, MPH
- Asian Development Bank
- Bill & Melinda Gates Foundation
- Duke Global Health Institute
- Harvard Kennedy School
- Harvard T.H. Chan School of Public Health
- Imperial College London Institute of Global health Innovation
- Results for Development (R4D)
- SEEK Development
- Stanford University Center for Innovation in Global Health
- UC Berkeley Center for Global Public Health
- UCSF Institute for Health Policy